18355-73-2

Basic information

• Product Name: 2,3-Difluorobenzoyl chloride
• Synonyms: 2,3-DIFLUOROBENZOYL CHLORIDE;2,3-Difluorobenzoyl chloride 98%;2,3-Difluorobenzoylchloride98%;3-(Chlorocarbonyl)-1,2-difluorobenzene;2,3-Difluorobenzoyl chloride, 98% 1GR
• CAS NO: 18355-73-2
• Molecular Formula: C₇H₃ClF₂O
• Molecular Weight: 176.55
• Product Categories: Miscellaneous;Acid Halides;Carbonyl Compounds;Organic Building Blocks;Fluorine series
• Mol File: 18355-73-2.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 85-87 °C14 mm Hg(lit.)
• Flash Point: 195 °F
• Appearance: Clear colorless liquid
• Density: 1.423 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.346mmHg at 25°C
• Refractive Index: n20/D 1.5143(lit.)
• Storage Temp.: Inert atmosphere,Room Temperature
• Sensitive: Moisture Sensitive
• BRN: 2965225
• CAS DataBase Reference: 2,3-Difluorobenzoyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-Difluorobenzoyl chloride(18355-73-2)
• EPA Substance Registry System: 2,3-Difluorobenzoyl chloride(18355-73-2)

Safety Data

• Hazard Codes: C
• Statements: 34-36/37
• Safety Statements: 23-26-27-36/37/39-45
• RIDADR: UN 3265 8/PG 2
• WGK Germany: 3
• HazardClass: 8
• PackingGroup: II
• Hazardous Substances Data: 18355-73-2(Hazardous Substances Data)

Usage

Description

2,3-Difluorobenzoyl chloride is a clear colorless liquid that is a derivative of benzoyl chloride with two fluorine atoms substituted at the 2nd and 3rd positions on the benzene ring. 2,3-Difluorobenzoyl chloride is known for its unique chemical properties and reactivity, making it a valuable intermediate in the synthesis of various organic compounds.

Uses

Used in Pharmaceutical Industry:
2,3-Difluorobenzoyl chloride is used as a key intermediate in the synthesis of N-(6-chloro-5-fluoro-1,3-benzothiazol-2-yl)-2,3-difluorobenzamide, a compound with potential pharmaceutical applications. Its unique structure and reactivity contribute to the development of new drugs with improved therapeutic properties.
Used in Organic Synthesis:
2,3

InChI:InChI=1/C7H3ClF2O/c8-7(11)4-2-1-3-5(9)6(4)10/h1-3H

Upstream product

• 4519-39-5 2,3-difluorobenzoic acid 

Downstream Products

• 16895-58-2 2H-1-benzothiopyran-3(4H)-one 
• 146173-66-2 4-(2,4-difluorobenzoyl)thiochroman-3-one 
• 219636-59-6 2,3-Difluoro-benzoic acid 2,6-di-tert-butyl-4-methoxy-phenyl ester 
• 860016-97-3 (2,3-difluorophenyl)-(thiophen-2-yl)methanone 
• 908336-75-4 2,3-difluoro-N-(4-chloro-2-hydroxyphenyl)-benzamide 
• 908336-72-1 2,3-difluoro-N-(5-chloro-2-hydroxyphenyl)-benzamide 
• 1002093-71-1 2,3-difluorobenzoyl cyanide 
• 902524-15-6 3-(2',3'-difluorophenyl)isocoumarin 
• 902524-19-0 2'-(2'',3''-difluorobenzoylmethyl)benzoic acid 
• 1011493-54-1 2-[2'-hydroxy-2'-(2'',3''-difluorophenyl)ethyl]benzoic acid 

Relevant articles and documents

Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors

A series of novel quinazoline derivatives bearing various C-6 benzamide substituents were synthesized and evaluated as EGFR inhibitors, and most showed significant inhibitory potency against EGFR kinase. In particular, compound 6g possessed potent inhibitory activity against EGFR wild-type (IC50 = 5 nM), and strong antiproliferative activity against HCC827 and Ba/F3 (L858R) cell lines. Kinase profiling against a panel of 365 kinases showed that 6g was highly selective for EGFR. Furthermore, 6g showed desirable properties in assays of liver microsome metabolic stability and cytochromes P450 inhibition and preliminary pharmacokinetic study. The overall attractive profile of 6g made it an interesting compound for further development.

N -pyridyl and pyrimidine benzamides as KCNQ2/Q3 potassium channel openers for the treatment of epilepsy

A series of N-pyridyl benzamide KCNQ2/Q3 potassium channel openers were identified and found to be active in animal models of epilepsy and pain. The best compound 12 [ICA-027243, N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide] has an EC50 of 0.38 μM and is selective for KCNQ2/Q3 channels. This compound was active in several rodent models of epilepsy and pain but upon repeated dosing had a number of unacceptable toxicities that prevented further development. On the basis of the structure-activity relationships developed around 12, a second compound, 51, [N-(2-chloro-pyrimidin-5-yl)-3,4-difluoro- benzamide, ICA-069673], was prepared and advanced into a phase 1 clinical study. Herein, we describe the structure-activity relationships that led to the identification of compound 12 and to the corresponding pyrimidine 51.

Synthesis and anti-inflammatory activity of fluorinated isocoumarins and 3,4-dihydroisocoumarins

The synthesis of several fluorinated isocoumarins and 3,4-dihydroisocoumarins are described. The structures of the synthesized compounds were confirmed by spectral and elemental analysis. All synthesized compounds were evaluated for their anti-inflammatory and antioxidant activity. These compounds were found to present antioxidant and anti-inflammatory activities. A few of them were found to be significantly active in vivo against ear edema in mice produced by 12-O-tetradecanoylphorbol-13-acetate (TPA) and also good radical scavengers.